Crossmark

Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

Crossref DOI link: https://doi.org/10.1186/s13075-018-1537-8

Published Online: 2018-03-01

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Caselli, Gianfranco https://orcid.org/0000-0002-1075-7408
Bonazzi, Albino

Lanza, Marco

Ferrari, Flora

Maggioni, Daniele

Ferioli, Cristian

Giambelli, Roberto

Comi, Eleonora

Zerbi, Silvia

Perrella, Marco

Letari, Ornella

Di Luccio, Elena

Colovic, Milena

Persiani, Stefano

Zanelli, Tiziano

Mennuni, Laura

Piepoli, Tiziana

Rovati, Lucio Claudio
More Information

Article History

Received: 21 November 2017

Accepted: 4 February 2018

First Online: 1 March 2018

Ethics approval and consent to participate

: PBMCs were prepared using whole blood obtained from healthy volunteers upon receiving their informed consent. Because the study presented no material ethical issues (samples anonymised and discarded immediately after analysis), the procedure was approved by the internal research ethics advisor. Animal studies were carried out in compliance with national and international laws and policies (Italian Legislative Decree 116/1992, and 26/2014 that transposed the EU Directive 86/609, and 2010/63/EU on the protection of animals used for scientific purposes) and were authorised by the Italian Ministry of Health (Decr. Min. number 60/2009-B, Decr. Min. number 214/2013-B, and Decr. Min. number 561/2017-PR).

: Not applicable.

: All of the authors are employees of Rottapharm Biotech.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.